ANIK stock news

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 25) Akero Therapeutics Inc (NASDAQ: AKRO ) Anika Therapeutics Inc (NASDAQ: ANIK )( reported better-than-expected second-quarter results) Novocure Ltd (NASDAQ: NVCR )(reported strong second-quarter results) Repligen Corporation (NASDAQ: RGEN ) Xenetic Biosciences Inc (NASDAQ: XBIO ) Baxter International Inc (NYSE: BAX ) (reacted to strong second-quarter results) West Pharmaceutical Services Inc. (NYSE: WST ) (reacted to strong second-quarter results) Myovant Sciences Ltd (NYSE: MYOV ) Down In The Dumps (Biotech stocks hitting 52-week lows on July 25) Abeona Therapeutics Inc (NASDAQ: ABEO )(announced results from a Phase 1/2 trial of its ABO-102, its gene therapy candidate for San Filippo syndrome Type A) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP )(announced initiation of trial dubbed SPEARHEAD-1 that is evaluating ADP-A2M4 SPEAR T cells for patients with synovial sarcoma or myxoid/round cell liposarcoma) Aduro BioTech Inc (NASDAQ: ADRO ) Alkermes Plc (NASDAQ: ALKS )(reacted to Q2 results) Alterity Therapeutics Ltd (NASDAQ: ATHE ) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) Aquestive Therapeutics Inc (NASDAQ: AQST ) Assembly Biosciences Inc (NASDAQ: ASMB ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) BENITEC BIOPHAR/S ADR (NASDAQ: BNTC ) ChemoCentryx Inc (NASDAQ: CCXI ) Dynavax Technologies Corporation (NASDAQ: DVAX ) Foamix Pharmaceuticals Ltd (NASDAQ: FOMX ) Gamida Cell Ltd (NASDAQ: GMDA ) GENFIT S A/ADR (NASDAQ: GNFT ) Innoviva Inc (NASDAQ: INVA )(reported below-consensus second-quarter results) Intercept Pharmaceuticals Inc (NASDAQ: ICPT ) Kaleido Biosciences Inc (NASDAQ: KLDO ) Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA ) Neon Therapeutics Inc (NASDAQ: … Read more
Anika (ANIK) delivered earnings and revenue surprises of 59.52% and 6.69%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock? Read more
On Anika Therapeutics' (ANIK) second-quarter earnings call, investor focus will be on its progress with the U.S. approval of its orthopedic product Cingal. Read more
Anika Therapeutics, Inc. (ANIK) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front. Read more
https://www.investing.com/analysis/will-anika-therapeutics-continue-to-surge-higher-200420663 Read more
The following slide deck was published by Anika Therapeutics, Inc. in conjunction with their 2019 Q1 earnings call. Read more
ANIK earnings call for the period ending March 31, 2019. Read more
Anika (ANIK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. Read more
Pune, India, April 17, 2019 (GLOBE NEWSWIRE) -- The global viscouspplementation market size can touch USD 5,243.19 million by 2023, expanding at 8.96% CAGR from 2018 to 2023 (forecast period), as per Market Research Future (MRFR). The ineffectiveness of nonsteroidal anti-inflammatory drugs (NSAIDs) and physical therapy have created the high market demand. Large prevalence of OAK is expected to be the major driver of the market. This can be attributed to high obesity rates and physical accidents which led to articular cartilage demand. According to the Center for Disease Control & Prevention (CDC), more than 30 million in the U.S. were diagnosed with osteoarthritis in 2015. Osteoarthritis of the knee (OAK) is a disease becoming highly prevalent among young adults and elder ones as well. Viscosupplementation products combined with hyaluronic acid which can be an effective treatment for providing lubrication and restoring mobility. Launches of novel products are predicted to bode well for the market growth in the forthcoming years. Read more
Anika Therapeutics Inc. (NASDAQ:ANIK) making news as their share price hit $30.24 at the end of the most recent trading day. Considering that price volatility is equivalent to risk, a commodity’s tr Read more
This is a contrast between ChemoCentryx Inc. (NASDAQ:CCXI) and Anika Therapeutics Inc. (NASDAQ:ANIK) based on their analyst recommendations, profitability, risk, dividends, earnings and valuation, ins Read more
Mustang Bio Inc. (NASDAQ:MBIO) and Anika Therapeutics Inc. (NASDAQ:ANIK) are two firms in the Biotechnology that compete against each other. Below is a comparison of their risk, analyst recommendation Read more

Proudly made at

ROCKIT